Advertisement

Topics

Roche-Tochter Genentech erhält für Zelobraf Priority Review gg Erdheim-Chester

09:28 EDT 7 Aug 2017 | FinanzNachrichten

Basel/South San Francisco (awp) - Die US-Gesundheitsbehörde FDA hat der Roche-Tochter Genentech ein beschleunigtes Zulassungsverfahren (Priority Review) für das Mittel Zelobraf (Vemurafenib) zugesp...

Original Article: Roche-Tochter Genentech erhält für Zelobraf Priority Review gg Erdheim-Chester

NEXT ARTICLE

More From BioPortfolio on "Roche-Tochter Genentech erhält für Zelobraf Priority Review gg Erdheim-Chester"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...